Precision medicine for brain arteriovenous malformations
Brain arteriovenous malformations (bAVMs) are dynamic, genetically driven lesions resulting from somatic mutations in KRAS, BRAF, and pathways involved in arteriovenous specification, angiogenesis, and vascular remodeling, leading to pediatric hemorrhagic stroke.
Recent studies have uncovered convergent mechanisms that link endothelial Ras/MAPK hyperactivation to abnormal vessel growth and higher rupture risk.
The authors believe precision medicine approaches that combine molecular diagnostics — such as liquid or endoluminal biopsies — with mutation-specific pharmacotherapies and emerging CRISPR-based gene editing strategies could be used to treat bAVMs.
